A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Pimavanserin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 03 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 15 Apr 2025.
- 06 Mar 2025 Planned initiation date (estimated date of first participant enrollement) changed from 15 Feb 2025 to 1 Mar 2025.
- 06 Mar 2025 Status changed from not yet recruiting to recruiting.